innat
immun
respons
first
line
defens
invad
viral
pathogen
mammalian
cell
encod
larg
number
incomplet
character
factor
imped
viru
replic
variou
stage
viru
replic
cycl
inhibitori
restrict
factor
either
express
constitut
induc
typei
interferon
ifn
one
restrict
factor
interfer
late
stage
viral
replic
cycl
tetherin
also
known
bone
marrow
stromal
antigen
cluster
differenti
inhibit
releas
human
immunodefici
viru
type
counteract
accessori
protein
vpu
tetherin
express
constitut
termin
differenti
b
cell
cell
identifi
marker
bone
marrow
stromal
cell
cancer
cell
amino
acid
type
ii
integr
membran
glycoprotein
tetherin
local
lipid
raft
cell
surfac
intracellular
membran
tetherin
homodimer
glycoprotein
contain
short
ntermin
cytoplasm
tail
ct
transmembran
tm
domain
rodlik
coiledcoil
cc
ectodomain
ctermin
glycosylphosphatidylinositol
gpi
anchor
ct
tetherin
contain
st
sequenc
implic
ubiquityl
highlyconserv
tyrosinebas
motif
yxxi
essenti
clathrindepend
endocytosi
tetherin
activ
nuclear
tm
gpi
anchor
provid
two
membran
anchor
enabl
tetherin
tether
virion
one
domain
viral
envelop
plasma
membran
pm
host
cell
specif
sequenc
tm
domain
implic
interact
tetherin
antagonist
vpu
ectodomain
human
tetherin
contain
three
cy
residu
requir
format
homodim
du
pont
et
al
recent
demonstr
disulfid
bond
requir
maintain
coiledcoil
dimer
structur
tetherin
howev
dimer
necessari
tetherin
antivir
activ
ectodomain
also
contain
two
asn
residu
posit
posttransl
modifi
nlink
oligosaccharid
delet
ct
tm
cc
gpi
domain
mutat
cy
residu
requir
protein
dimer
abrog
abil
tetherin
inhibit
viru
releas
tetherin
inhibit
releas
also
broad
spectrum
envelop
virus
includ
alphavirus
filovirus
rhabdovirus
arenavirus
herpesvirus
paramyxovirus
flavivirus
orthohepadnavirus
orthomyxovirus
retrovirus
review
mani
virus
evolv
divers
strategi
antagon
tetherin
vpu
counteract
human
tetherin
reduc
cellsurfac
express
via
lysosom
proteasom
degrad
trap
tetherin
intracellularli
andor
prevent
recycl
back
pm
specif
vpu
toward
tetherin
antagon
also
vari
speci
speci
vpu
counteract
tetherin
human
chimpanze
gorilla
howev
rel
inact
tetherin
nonhuman
primat
nonprim
simian
immunodefici
viru
siv
encod
vpu
gene
antagon
tetherin
nef
envelop
env
protein
respect
part
intracellular
sequestr
mechan
mention
human
tetherin
contain
two
put
nlink
glycosyl
site
extracellular
cc
domain
requir
tetherin
glycosyl
inhibit
viru
releas
remain
controversi
earli
studi
report
nlink
glycosyl
asn
import
inhibit
releas
howev
studi
found
mutat
neglig
effect
tetherin
restrict
releas
studi
report
correl
tetherin
restrict
viru
releas
tetherin
cellsurfac
express
other
observ
correl
studi
carri
human
tetherin
other
use
tetherin
speci
studi
also
differ
use
viral
system
examin
tetherin
restrict
studi
carri
wherea
other
use
felin
immunodefici
viru
prototyp
foami
viru
xenotrop
murin
leukemia
virusrel
viru
bovin
leukemia
viru
sever
acut
respiratori
syndrom
sar
coronaviru
lassa
fever
viru
marburg
virus
asnlink
nlink
glycosyl
highli
regul
posttransl
modif
import
structur
function
eukaryot
protein
nlink
glycosyl
initi
lumen
endoplasm
reticulum
er
cotransl
transfer
highmannos
oligosaccharid
moieti
asn
residu
asnxserthr
motif
x
amino
acid
except
pro
target
protein
trim
highmannos
side
chain
occur
er
golgi
apparatu
addit
sugar
eg
galactos
fucos
sialic
acid
attach
gener
complex
side
chain
glycoprotein
export
pm
secretori
pathway
transient
overexpress
cell
sever
form
tetherin
detect
nonglycosyl
speci
form
bear
highmannos
modif
either
kda
kda
asn
complextyp
carbohydr
either
posit
kda
studi
carri
detail
investig
whether
tetherin
glycosyl
essenti
abil
inhibit
releas
employ
glycosylationsit
tetherin
mutant
chemic
inhibitor
glycosyl
pathway
observ
oligosaccharid
modif
one
two
site
tetherin
nlink
glycosyl
necessari
suffici
tetherinmedi
restrict
releas
complextyp
glycosyl
dispens
tetherin
antivir
function
fulllength
infecti
molecular
clone
vpudefect
counterpart
describ
previous
kindli
provid
k
strebel
nation
institut
health
nih
bethesda
md
usa
vector
express
tetherin
deriv
bear
ntermin
hemagglutinin
ha
epitop
tag
ha
tag
insert
residu
extracellular
cc
domain
tetherin
describ
previous
gener
provid
p
bieniasz
rockefel
univers
new
york
ny
usa
pcrbase
mutagenesi
use
introduc
ala
substitut
either
one
two
asn
residu
target
nlink
glycosyl
antiha
antiserum
kifunensin
tunicamycin
purchas
sigma
st
loui
mo
usa
alexa
fluor
secondari
antibodi
invitrogen
grand
island
ny
usa
antivpu
antitetherin
immunoglobulin
ig
obtain
nih
aid
research
refer
reagent
program
hela
cell
line
maintain
dulbeccomodifi
eagl
medium
dmem
contain
fetal
bovin
serum
fb
respect
one
day
plate
cell
transfect
appropri
plasmid
dna
use
lipofectamin
invitrogen
corp
carlsbad
ca
usa
accord
manufactur
recommend
eight
hour
transfect
cell
either
untreat
treat
overnight
tunicamycin
kifunensin
cell
viru
harvest
post
transfect
use
analysi
knock
tetherin
express
hela
cell
one
day
plate
hela
cell
treat
nm
tetherin
small
interf
rna
sirna
dharmacon
lafayett
co
usa
oligofectamin
transfect
reagent
invitrogen
h
hela
cell
transfect
molecular
clone
virion
collect
h
pellet
ultracentrifug
cell
viru
pellet
lyse
buffer
contain
mm
trishcl
ph
mm
nacl
mm
edta
triton
proteas
inhibitor
cocktail
roch
life
scienc
basel
switzerland
denatur
boil
sampl
buffer
protein
subject
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
transfer
polyvinyliden
difluorid
pvdf
membran
incub
appropri
antibodi
describ
text
membran
incub
horseradish
peroxidas
hrp
conjug
secondari
antibodi
chemiluminesc
signal
detect
use
west
pico
west
femto
chemiluminesc
reagent
thermo
fisher
scientif
waltham
usa
protein
band
quantifi
use
imagelabchemidoc
biorad
laboratori
marneslacoquett
franc
one
day
plate
hela
cell
transfect
wildtyp
wt
vpudefect
molecular
clone
oneday
post
transfect
virion
pellet
ultracentrifug
cell
viru
pellet
lyse
viral
protein
cell
viru
lysat
immunoblot
hivig
viru
releas
effici
calcul
amount
virionassoci
fraction
total
cellassoci
plu
virionassoci
gag
cell
transfect
wt
mutant
human
tetherin
express
vector
ha
tag
insert
cc
extracellular
domain
tetherin
green
fluoresc
protein
gfp
express
plasmid
hela
transfect
cell
either
untreat
treat
glycosyl
inhibitor
tunicamycin
kifunensin
twentyfour
hour
transfect
treatment
inhibitor
cell
harvest
ad
solut
mm
edta
phosphat
buffer
salin
pb
wash
icecold
bovin
serum
albumin
bsa
pb
cell
incub
antiha
mous
antitetherin
rabbit
antiserum
bsapb
h
cell
wash
twice
bsapb
stain
alexa
fluor
antimous
cell
alexa
fluor
antirabbit
hela
cell
igg
secondari
antibodi
bsapb
h
cell
wash
three
time
pb
fix
paraformaldehyd
gate
event
collect
use
becton
dickinson
fluorescenceactiv
cell
sort
fac
calibur
flow
cytomet
bd
bioscienc
hampton
nh
usa
analysi
perform
use
flowjo
treestar
palo
alto
ca
usa
microscopi
studi
hela
cell
cultur
chamber
slide
one
day
plate
cell
untreat
treat
kifunensin
transfect
sirna
target
tetherin
h
cell
rins
pb
fix
paraformaldehyd
pb
min
cell
rins
pb
three
time
block
bsapb
min
incub
antitetherin
antibodi
appropri
dilut
bsapb
h
cell
wash
pb
three
time
incub
secondari
antibodi
conjug
alexa
fluor
dilut
bsapb
wash
pb
three
time
cell
mount
vectashield
mount
media
dapi
vector
laboratori
burlingam
ca
usa
examin
deltavis
rt
deconvolut
microscop
ge
healthcar
life
scien
pittsburg
pa
usa
discuss
introduct
requir
nlink
glycosyl
tetherin
antivir
function
remain
clearli
establish
defin
role
nlink
glycosyl
human
tetherin
releas
use
two
molecular
clone
lack
function
vpu
vpudelet
mutant
stop
codon
amino
acid
residu
vpu
transfect
cell
express
endogen
tetherin
wt
vpudefect
analyz
viru
releas
presenc
wt
glycosylationdefect
singl
doubl
mutant
human
tetherin
shown
figur
wt
human
tetherin
inhibit
releas
delvpu
udel
fivefold
wherea
releas
wt
vpu
significantli
reduc
condit
vpu
express
reduc
tetherin
level
compar
figur
lane
report
previous
doubl
mutant
unabl
inhibit
releas
quantifi
figur
lack
inhibitori
activ
due
reduc
express
level
mutant
mutant
express
higher
level
wt
singl
asn
mutant
figur
glycosyl
tetherin
appear
critic
stabil
singl
doubl
mutant
express
least
well
wt
report
previous
singl
mutant
inhibit
releas
delvpu
udel
particl
similar
extent
wt
tetherin
figur
studi
indic
glycosyl
least
one
asn
human
tetherin
necessari
suffici
inhibit
releas
condit
investig
role
glycosyl
tetherin
function
overexpress
wt
tetherin
cell
treat
cell
tunicamycin
nucleosid
antibiot
specif
inhibit
first
step
nlink
glycosyl
block
transfer
dolichol
phosphat
shown
figur
treat
cell
tunicamycin
result
complet
loss
glycosyl
wt
tetherin
demonstr
observ
mobil
tetherin
speci
match
nonglycosyl
doubl
mutant
consist
data
glycosylationsit
mutant
complet
loss
glycosyl
impos
tunicamycin
treatment
littl
effect
tetherin
express
confirm
unlik
glycoprotein
env
tetherin
stabil
requir
glycosyl
interestingli
tunicamycin
treatment
significantli
disrupt
abil
wt
tetherin
inhibit
releas
vpudefect
figur
increas
viru
releas
upon
tunicamycin
treatment
similar
observ
upon
mutat
figur
tunicamycin
treatment
effect
viru
releas
presenc
nonglycosyl
tetherin
mutant
result
support
conclus
glycosyl
tetherin
necessari
abil
inhibit
releas
discuss
earlier
conflict
report
literatur
surfac
express
glycosylationdefect
tetherin
mutant
author
report
cellsurfac
express
mutant
significantli
reduc
slightli
reduc
reduc
rel
wt
tetherin
measur
cellsurfac
express
glycosylationdefect
mutant
express
wt
tetherin
ha
tag
insert
residu
extracellular
cc
domain
stain
antiha
antibodi
detail
materi
method
section
doubl
mutant
tetherin
express
lower
level
cell
surfac
rel
wt
figur
increas
cellsurfac
express
mutant
tetherin
transfect
cell
increas
amount
wt
tetherin
express
vector
although
proport
increas
total
cellular
express
tetherin
increas
amount
transfect
dna
wt
tetherin
figur
median
fluoresc
intens
mutant
tetherin
increas
proport
increas
amount
doubl
mutant
observ
support
conclus
tetherin
defect
cellsurfac
express
figur
even
tetherin
express
vector
input
cellsurfac
express
lower
achiev
upon
transfect
wt
tetherin
express
vector
signific
decreas
viru
releas
effici
vre
input
express
vector
howev
small
decreas
vre
input
dna
figur
c
contrast
mark
proport
decreas
vre
increas
amount
wt
tetherin
dna
result
demonstr
glycosyl
requir
proper
transport
tetherin
cell
surfac
abil
inhibit
viru
releas
discuss
introduct
tetherin
express
sever
form
nonglycosyl
speci
speci
contain
singl
highmannos
side
chain
either
asn
kda
highmannos
side
chain
asn
residu
kda
complextyp
side
chain
either
posit
kda
figur
next
ask
whether
complextyp
glycosyl
tetherin
necessari
inhibitori
activ
answer
question
util
kifunensin
alkaloid
compound
inhibit
activ
erassoci
mannosidas
enzym
requir
trim
convers
highmannos
complextyp
side
chain
cell
treat
kifunensin
loss
complextyp
glycosyl
tetherin
demonstr
compound
activ
figur
despit
loss
complextyp
oligosaccharid
modif
kifunensin
treatment
littl
effect
abil
tetherin
inhibit
releas
vpudefect
figur
b
experi
carri
overexpress
tetherin
cell
also
test
effect
kifunensin
endogen
tetherin
hela
cell
observ
kifunensin
treatment
effect
inhibitori
activ
tetherin
figur
expect
kifunensin
treatment
shift
endogen
tetherin
complextyp
highmannosemodifi
speci
figur
result
demonstr
complextyp
glycosyl
dispens
tetherin
inhibit
releas
context
endogen
exogen
express
protein
result
demonstr
complextyp
glycosyl
tetherin
requir
inhibitori
function
sinc
cellsurfac
express
tetherin
necessari
inhibit
viru
releas
observ
would
suggest
complextyp
oligosaccharid
modif
requir
cellsurfac
tetherin
express
directli
examin
question
hela
cell
treat
kifunensin
h
test
cellsurfac
express
endogen
tetherin
microscopi
flow
cytometri
shown
figur
immunofluoresc
microscopi
suggest
kifunensin
treatment
littl
effect
cellsurfac
express
endogen
tetherin
hela
cell
control
knockeddown
tetherin
express
use
sirna
expect
observ
complet
loss
cellsurfac
express
tetherin
knockdown
tetherin
sirnatr
hela
cell
determin
quantit
western
blot
data
shown
flow
cytometri
analysi
confirm
cellsurfac
express
tetherin
hela
cell
diminish
kifunensin
treatment
wherea
knockdown
tetherin
markedli
reduc
cellsurfac
express
figur
shown
figur
glycosyl
least
one
asn
requir
tetherinmedi
inhibit
releas
determin
whether
complextyp
oligosaccharid
modif
tetherin
glycosyl
singl
residu
also
dispens
inhibit
viru
releas
cell
transfect
wt
tetherin
mutant
treat
kifunensin
h
viru
releas
monitor
observ
wt
tetherin
inhibit
releas
singl
asn
mutant
diminish
presenc
kifunensin
figur
b
expect
kifunensin
treatment
result
express
tetherin
speci
complextyp
tetherin
kda
singleasn
mutant
figur
result
indic
complextyp
glycosyl
even
singleasn
mutant
dispens
inhibit
viru
releas
also
test
whether
prevent
complextyp
glycosyl
singl
asn
effect
surfac
express
tetherin
mutant
cell
transfect
wt
mutant
tetherin
express
vector
carri
hatag
extracellular
cc
domain
transfect
cell
stain
antiha
antibodi
although
median
fluoresc
intens
cellsurfac
tetherin
wt
singl
glycosyl
mutant
slightli
reduc
kifunensin
treatment
still
remain
consider
amount
cellsurfac
tetherin
follow
kifunensin
treatment
figur
howev
wt
tetherinexpress
cell
treat
tunicamycin
mark
reduct
cellsurfac
express
tetherin
suggest
highmannos
glycosyl
tetherin
complextyp
glycosyl
requir
cellsurfac
express
figur
result
confirm
find
complextyp
glycosyl
tetherin
dispens
cellsurfac
express
inhibit
releas
demonstr
singl
highmannos
modif
tetherin
suffici
cellsurfac
tetherin
express
antivir
activ
uniqu
topolog
tetherin
allow
bind
restrict
releas
virion
surfac
infect
cell
sever
structur
domain
tetherin
includ
ct
tm
domain
gpi
anchor
dimer
motif
cc
region
ectodomain
critic
tetherin
antivir
activ
howev
role
nlink
glycosyl
tetherin
function
remain
poorli
defin
studi
carri
detail
investig
role
nlink
glycosyl
antivir
activ
human
tetherin
use
nonglycosyl
tetherin
mutant
also
chemic
inhibitor
glycosyl
pathway
data
indic
nlink
glycosyl
least
one
asn
residu
tetherin
requir
inhibit
releas
mutat
singl
site
nlink
glycosyl
impact
antivir
activ
human
tetherin
singl
mutant
effici
express
cell
surfac
suggest
nlink
glycosyl
singl
asn
suffici
traffick
pm
contrast
doubl
mutant
defect
cellsurfac
express
inhibit
releas
loss
cellsurfac
express
antivir
activ
could
rescu
increas
total
express
mutant
consist
data
perezcaballero
et
al
show
nlink
glycosyl
tetherin
essenti
cellsurfac
express
lab
also
report
nlink
glycosyl
essenti
inhibit
releas
tokarev
et
al
observ
mutat
asn
residu
markedli
impair
abil
tetherin
restrict
viru
releas
induc
activ
loss
antivir
activ
mutant
toward
virus
xenotrop
murin
leukemia
virusrel
viru
xmrv
also
report
taylor
et
al
demonstr
human
tetherin
restrict
sarscov
egress
sarscov
protein
directli
interact
tetherin
inhibit
glycosyl
antivir
function
observ
tetherin
mutant
mistraffick
accumul
intracellular
compart
interestingli
nonglycosyl
tetherin
mutant
still
abl
inhibit
releas
matrix
mutant
assembl
multivesicular
bodi
mvb
also
inhibit
mvbassoci
hepat
b
viru
hbv
requir
nlink
glycosyl
antivir
activ
felin
tetherin
also
report
slight
impair
antivir
activ
bovin
tetherin
observ
upon
mutat
singl
glycosyl
site
tetherin
owl
monkey
kidney
cell
line
shown
restrict
due
presenc
thr
residu
prevent
effici
glycosyl
mutat
thr
ile
rescu
glycosyl
antivir
function
studi
consist
import
nlink
glycosyl
tetherin
activ
contrast
sever
group
report
glycosyl
human
tetherin
essenti
restrict
releas
foami
viru
lassa
marburg
virus
differ
observ
among
differ
group
like
due
differ
level
tetherin
express
use
differ
approach
measur
viru
releas
studi
discuss
carri
asn
mutant
tetherin
defect
glycosyl
contrast
previou
studi
also
adopt
complementari
approach
use
chemic
inhibitor
glycosyl
pathway
treat
cell
tunicamycin
inhibit
first
step
nlink
glycosyl
block
glycosyl
cellsurfac
express
antivir
activ
tetherin
manner
similar
doubl
mutant
also
evalu
whether
complex
glycosyl
tetherin
essenti
antivir
activ
treat
cell
mannosidas
inhibitor
kifunensin
result
loss
complex
glycosyl
wt
tetherin
loss
cellsurfac
express
antivir
function
similarli
cellsurfac
express
antivir
activ
singl
asn
mutant
diminish
kifunensin
treatment
result
indic
mannos
trim
activ
mannosidas
requir
convers
highmannos
complex
oligosaccharid
side
chain
requir
cellsurfac
express
antivir
activ
tetherin
conclus
show
glycosyl
least
one
asn
essenti
complex
side
chain
modif
dispens
cellsurfac
express
antivir
activ
human
tetherin
studi
provid
new
insight
number
oligosaccharid
side
chain
requir
tetherin
transport
activ
also
role
oligosaccharid
modif
function
